Antiretroviral treatment for HIV infection: Swedish recommendations 2016

References

• UNAIDS. AIDS by the numbers 2015. UNAIDS, 2015.
   Google Scholar
• Wohl D, Oka S, Clumeck N, et al. Team G-U-S. A randomized, double-blind comparison of tenofovir alafenamide (TAF) vs. tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016;72:58–64.
   PubMed Web of Science ®Google Scholar
• Sax PE, Wohl D, Yin MT, et al. Team G-U-S. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606–2615.
   PubMed Web of Science ®Google Scholar
• Brännström J, Svedhem Johansson V, Yilmaz A, et al. A high occurrence of late presenters and missed HIV diagnosis in clinical care in Sweden. J Int AIDS Soc. 2010;13:169.
   Google Scholar
• Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4:e5575.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725–733.
   PubMed Web of Science ®Google Scholar
• Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257–265.
   PubMed Web of Science ®Google Scholar
• Strategies for Management of Antiretroviral Therapy Study Group, Emery S, Neuhaus JA, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133–1144.
   PubMed Web of Science ®Google Scholar
• May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21:1185–1197.
   PubMed Web of Science ®Google Scholar
• Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815–1826.
   PubMed Web of Science ®Google Scholar
• HIV-CAUSAL Collaboration, Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 2011;154:509–515.
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
   PubMed Web of Science ®Google Scholar
• Folkhälsomyndigheten. Smittsamhet vid behandlad hivinfektion. Östersund, Sweden: The Public Health Agancy of Sweden, 2014.
   Google Scholar
• Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49:1898–1906.
   PubMed Web of Science ®Google Scholar
• Garrett KL, Cottrell ML, Prince HM, et al. Concentrations of TFV and TFVdp in female mucosal tissues after a single dose of TAF. Abstract 102LB, CROI, Boston, USA; 2016.
   Google Scholar
• Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095–2106.
   PubMed Web of Science ®Google Scholar
• Daar AS, Tierney C, Fischl MA, et al. Final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment naive HIV-infected patients. In: 17th conference on retroviruses and opportunistic infections. San Francisco, USA; 2010.
   Google Scholar
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13:927–935.
   PubMed Web of Science ®Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796–806.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63:77–85.
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–1818.
   PubMed Web of Science ®Google Scholar
• Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222–2231.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039–2046.
   PubMed Web of Science ®Google Scholar
• Hamada Y, Nishijima T, Komatsu H, et al. Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?. PLoS One. 2013;8:e69845.
   PubMed Web of Science ®Google Scholar
• Lin KY, Liao SH, Liu WC, et al. Cholelithiasis and nephrolithiasis in HIV-positive patients in the era of combination antiretroviral therapy. PLoS One. 2015;10:e0137660.
   PubMed Web of Science ®Google Scholar
• Leon A, Martinez E, Mallolas J, et al. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS. 2005;19:213–215.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62:483–486.
   PubMed Web of Science ®Google Scholar
• Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63:96–100.
   PubMed Web of Science ®Google Scholar
• Ekici H, Amogne W, Aderaye G, et al. Minority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCR. PLoS One. 2014;9:e111042.
   PubMed Web of Science ®Google Scholar
• Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011;305:1327–1335.
   PubMed Web of Science ®Google Scholar
• Metzner KJ, Scherrer AU, von Wyl V, et al. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. AIDS. 2014;28:2231–2239.
   PubMed Web of Science ®Google Scholar
• Mills AM, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin Trials. 2013;14:216–223.
   PubMed Web of Science ®Google Scholar
• Aleman S, Soderbarg K, Visco-Comandini U, et al. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS. 2002;16:1039–1044.
   PubMed Web of Science ®Google Scholar
• Vandamme AM, Sonnerborg A, Ait-Khaled M, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther (Lond.). 2004;9:829–848.
   PubMed Web of Science ®Google Scholar
• Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the randomized evaluation of strategic intervention in multi-drug resistant patients with tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466–475.
   PubMed Web of Science ®Google Scholar
• Youle M, Staszweski S, Clotet B, et al. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. HIV. Clin Trials. 2006;7:86–96.
   Web of Science ®Google Scholar
• Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535–540.
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Lundgren J, Neaton JD, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.
   PubMed Web of Science ®Google Scholar
• Mellberg T, Krabbe J, Gisslen M, et al. HIV-1 low copy viral sequencing-A prototype assay. Infect Dis (Lond). 2016;48:472–476.
   PubMed Web of Science ®Google Scholar
• Vandekerckhove LP, Wensing AM, Kaiser R, et al. European Consensus Group on clinical management of tropism testing. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis. 2011;11:394–407.
   PubMed Web of Science ®Google Scholar
• Sun XW, Kuhn L, Ellerbrock TV, et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997;337:1343–1349.
   PubMed Web of Science ®Google Scholar
• Carlander C, Wagner P, Svedhem V, et al. Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden. Int J Cancer. 2016;139:1471–1479.
   PubMed Web of Science ®Google Scholar
• Konopnicki D, Manigart Y, Gilles C, et al. Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women. J Infect Dis. 2013;207:1723–1729.
   PubMed Web of Science ®Google Scholar
• Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis. 2010;201:681–690.
   PubMed Web of Science ®Google Scholar
• Firnhaber C, Westreich D, Schulze D, et al. Highly active antiretroviral therapy and cervical dysplasia in HIV-positive women in South Africa. J Int AIDS Soc. 2012;15:17382.
   PubMed Web of Science ®Google Scholar
• Zeier MD, Nachega JB, Van Der Merwe FH, et al. Impact of timing of antiretroviral therapy initiation on survival of cervical squamous intraepithelial lesions: a cohort analysis from South Africa. Int J STD AIDS. 2012;23:890–896.
   PubMed Web of Science ®Google Scholar
• Keller MJ, Burk RD, Xie X, et al. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. JAMA. 2012;308:362–369.
   PubMed Web of Science ®Google Scholar
• Keller MJ, Burk RD, Massad LS, et al. Cervical precancer risk in HIV-infected women who test positive for oncogenic human papillomavirus despite a normal Pap test. Clin Infect Dis. 2015;61:1573–1581.
   PubMed Web of Science ®Google Scholar
• EACS. EACS Guidelines 8.0: European AIDS Clinical Society. Copenhagen, Denmark: 2015.
   Google Scholar
• Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011;121:4593–4599.
   PubMed Web of Science ®Google Scholar
• Schim van der Loeff MF, Mooij SH, Richel O, et al. HPV and anal cancer in HIV-infected individuals: a review. Curr HIV/AIDS Rep. 2014;11:250–262.
   PubMed Web of Science ®Google Scholar
• Ford N, Shubber Z, Calmy A, et al. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review. Clin Infect Dis. 2015;60:S170–S176.
   PubMed Web of Science ®Google Scholar
• Folkhälsomyndigheten. Uppföljningstid efter hivexposition Folkhälsomyndigheten, 2015.
   Google Scholar
• Gaines H, Albert J, Axelsson M, et al. Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Infect Dis (Lond). 2016;48:93–98.
   PubMed Web of Science ®Google Scholar
• McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60.
   PubMed Web of Science ®Google Scholar
• Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237–2246.
   PubMed Web of Science ®Google Scholar
• Cairns G, McCormack S, Molina JM. The European preexposure prophylaxis revolution. Curr Opin HIV AIDS. 2016;11:74–79.
   PubMed Web of Science ®Google Scholar
• Albert J, Berglund T, Gisslen M, et al. Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Scand J Infect Dis. 2014;46:673–677.
   PubMed Web of Science ®Google Scholar
• Rodger A, Bruun T, Cambiano V, et al. HIV transmission risk through condomless sex if HIV + partner on suppressive ART: PARTNER Study. CROI. 2016;2016 Abstract 153LB.
   Google Scholar
• Socias ME, Sued O, Laufer N, et al. Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. J Int AIDS Soc. 2011;14:40.
   PubMed Web of Science ®Google Scholar
• Lodi S, Phillips A, Touloumi G, et al. EuroCoord CCi. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm(3): assessment of need following changes in treatment guidelines. Clin Infect Dis. 2011;53:817–825.
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523–526.
   PubMed Web of Science ®Google Scholar
• Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012;205:87–96.
   PubMed Web of Science ®Google Scholar
• SPARTAC Trial Investigators, Fidler S, Porter K, Ewings F, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 2013;368:207–217.
   PubMed Web of Science ®Google Scholar
• Grijsen ML, Steingrover R, Wit FW, et al. Primo SHMSG. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med. 2012;9:e1001196.
   PubMed Web of Science ®Google Scholar
• Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis. 2005;191:1410–1418.
   PubMed Web of Science ®Google Scholar
• Brannstrom J, Svedhem Johansson V, Marrone G, et al. Deficiencies in the health care system contribute to a high rate of late HIV diagnosis in Sweden. HIV Med. 2016;17:425–435.
   PubMed Web of Science ®Google Scholar
• Egnell K, Svedhem Johansson V. 23% of newly diagnosed HIV in 2007 at Karolinska University Hospital had opprtunistic infections. J Int AIDS Soc 2008;11(Suppl 1):P256.
   Google Scholar
• Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–1799.
   PubMed Web of Science ®Google Scholar
• Gilleece Y, Chadwick DR, Breuer J, et al. British HIV association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med. 2010;11:611–619.
   PubMed Web of Science ®Google Scholar
• Camacho RJ. Special aspects of the treatment of HIV-2-infected patients. Intervirology. 2012;55:179–183.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182–189.
   PubMed Web of Science ®Google Scholar
• Nunez M, Lana R, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:426–431.
   PubMed Web of Science ®Google Scholar
• Koziel MJ. Influence of HIV co-infection on hepatitis C immunopathogenesis. J Hepatol. 2006;44:S14–S18.
   PubMed Web of Science ®Google Scholar
• Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590–598.
   PubMed Web of Science ®Google Scholar
• Läkemedelverket och RAV. Läkemedelsbehandling av hepatit C-virusinfektion hos vuxna och barn ? behandlingsrekommendation. Information från Läkemedelsverket 4:2015: 44–56.
   Google Scholar
• Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine. 2000;18:1161–1165.
   PubMed Web of Science ®Google Scholar
• WHO. HIV associated tuberculosis - TB/HIV fact sheet. Geneva, Switzerland: World Health Organization, 2015.
   Google Scholar
• Folkhälsomyndigheten. Tuberkulos under 2015. Folkhälsomyndigheten, 2016.
   Google Scholar
• Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis. 2010;50:1532–1538.
   PubMed Web of Science ®Google Scholar
• Boulware DM, Muzoora C. ART initiation within the first 2 weeks of cryptococcal meningitis is associated with higher mortality: a multisite randomized trial (Abstract #144). In: 20th Conference on Retroviruses and Opportunistic Infections. 2013.
   Google Scholar
• Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370:2487–2498.
   PubMed Web of Science ®Google Scholar
• Costiniuk CT, Fergusson DA, Doucette S, Angel JB. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/microL and virologic suppression: a systematic review. PLoS One. 2011;6:e28570.
   PubMed Web of Science ®Google Scholar
• Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America; [cited 2016 Oct 21]. Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.
   Google Scholar
• Kojic EM, Kang M, Cespedes MS, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014;59:127–135.
   PubMed Web of Science ®Google Scholar
• Levin CE, Sellors J, Shi JF, et al. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer. 2010;127:1404–1411.
   PubMed Web of Science ®Google Scholar
• Giacomet V, Penagini F, Trabattoni D, et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine. 2014;32:5657–5661.
   PubMed Web of Science ®Google Scholar
• Kojic EM, Rana AI, Cu-Uvin S. Human papillomavirus vaccination in HIV-infected women: need for increased coverage. Expert Rev Vaccines. 2016;15:105–117.
   PubMed Web of Science ®Google Scholar
• Naver L, Lindgren S, Belfrage E, et al. Children born to HIV-1-infected women in Sweden in 1982–2003: trends in epidemiology and vertical transmission. J Acquir Immune Defic Syndr. 2006;42:484–489.
   PubMed Web of Science ®Google Scholar
• McIntosh K, Shevitz A, Zaknun D, et al. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J. 1996;15:1087–1091.
   PubMed Web of Science ®Google Scholar
• Walker AS, Doerholt K, Sharland M, Collaborative HIVPSSC, et al. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS. 2004;18:1915–1924.
   PubMed Web of Science ®Google Scholar
• Dunn D, Woodburn P, Duong T, et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis. 2008;197:398–404.
   PubMed Web of Science ®Google Scholar
• Age-related standards for T lymphocyte subsets based on uninfected children born to human immunodeficiency virus 1-infected women. The European Collaborative Study. Pediatr Infect Dis J. 1992;11:1018–1026.
   PubMed Web of Science ®Google Scholar
• Study HIVPPMC, Boyd K, Dunn DT, et al. Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS. 2010;24:1213–1217.
   PubMed Web of Science ®Google Scholar
• Dunn D. Group HIVPPMCS. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 2003;362:1605–1611.
   PubMed Web of Science ®Google Scholar
• Ruel TD, Boivin MJ, Boal HE, et al. Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis. 2012;54:1001–1009.
   PubMed Web of Science ®Google Scholar
• Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233–2244.
   PubMed Web of Science ®Google Scholar
• Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age. Cochrane Database Syst Rev. 2014;5:CD004772.
   Google Scholar
• Lewis J, Walker AS, Castro H, et al. Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. J Infect Dis. 2012;205:548–556.
   PubMed Web of Science ®Google Scholar
• Cagigi A, Rinaldi S, Cotugno N, et al. Early highly active antiretroviral therapy enhances B-cell longevity: a 5 year follow up. Pediatr Infect Dis J. 2014;33:e126–e131.
   PubMed Web of Science ®Google Scholar
• Jesson J, Koumakpai S, Diagne NR, et al. Effect of age at antiretroviral therapy initiation on catch-up growth within the first 24 months among HIV-infected children in the IeDEA West African Pediatric Cohort. Pediatr Infect Dis J. 2015;34:e159–e168.
   Web of Science ®Google Scholar
• Persaud D, Patel K, Karalius B, et al. Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr. 2014;168:1138–1146.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Revised surveillance case definition for HIV infection–United States, 2014. MMWR Recomm Rep. 2014;63:1–10.
   Web of Science ®Google Scholar
• Lowenthal ED, Ellenberg JH, Machine E, et al. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. JAMA. 2013;309:1803–1809.
   PubMed Web of Science ®Google Scholar
• Mukonzo JK, Okwera A, Nakasujja N, et al. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis. 2013;13:261.
   PubMed Web of Science ®Google Scholar
• United States Department of Health and Human Services. FDA Drug Safety Communication: Serious health problems seen in premature babies given Kaletra (lopinavir/ritonavir) oral solution; [cited 2011 Aug 3]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm246002.htm.
   Google Scholar
• Westling K, Naver L, Vesterbacka J, et al. Transition of HIV-infected youths from paediatric to adult care, a Swedish single-centre experience. Infect Dis (Lond). 2016;48:449–452.
   PubMed Web of Science ®Google Scholar
• EMA. Updated advice on body fat changes and lactic acidosis with HIV medicines. European Medicines Agency 2015.
   Google Scholar
• Keiser PH, Sension MG, DeJesus E, Team ESSS, et al. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis 2005;5:2.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Domingo P, Palacios R, et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS. 2006;20:1407–1414.
   PubMed Web of Science ®Google Scholar
• Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr. 2005;39:174–180.
   PubMed Web of Science ®Google Scholar
• EACPR. SCORE – European High Risk Chart. In: Rehabilitation EAfCPa, editor. Avialable from: http://wwwescardioorg/static_file/Escardio/Subspecialty/EACPR/Documents/score-chartspdf2012.
   Google Scholar
• Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Group NACT, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569–577.
   PubMed Web of Science ®Google Scholar
• Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45:3445–3450.
   PubMed Web of Science ®Google Scholar
• Servoss JC, Kitch DW, Andersen JW, et al. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989–1999). J Acquir Immune Defic Syndr. 2006;43:320–323.
   PubMed Web of Science ®Google Scholar
• Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283–290.
   PubMed Web of Science ®Google Scholar
• Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482–487.
   PubMed Web of Science ®Google Scholar
• Yombi JC, Pozniak A, Boffito M, et al. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS. 2014;28:621–632.
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–732.
   PubMed Web of Science ®Google Scholar
• Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U.S.A. 2004;101:4180–4185.
   PubMed Web of Science ®Google Scholar
• Orkin C, Wang J, Bergin C, et al. An epidemiologic study to determine the prevalence of the HLA- B*5701 allele among HIV-positive patients in Europe. Pharmacogenet Genomics. 2010;20:307–314.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–579.
   PubMed Web of Science ®Google Scholar
• Aslangul E, Assoumou L, Bittar R, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS. 2010;24:77–83.
   PubMed Web of Science ®Google Scholar
• Singh S, Willig JH, Mugavero MJ, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis. 2011;52:387–395.
   PubMed Web of Science ®Google Scholar
• Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol. 1998;46:111–116.
   PubMed Web of Science ®Google Scholar
• Dresser GK, Schwarz UI, Wilkinson GR, et al. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther. 2003;73:41–50.
   PubMed Web of Science ®Google Scholar